

RESEARCH ARTICLE

OPEN ACCESS

Identification of ESBL-producing *Escherichia coli* Carrying Genes Coding Aminoglycosides Modifying Enzymes Isolated from Urinary Tract Infection Patients in Sana'a City, Yemen

Siham A. Al-Arosi*, Saleh S. Bahaj and Ahmed Y. Al-Jaufy

Department of Medical Microbiology and Clinical Immunology, Faculty of Medicine and Health Sciences, Sana'a University, Sanaa, Republic of Yemen.

Abstract

Resistance to antibiotics poses a major challenge, especially in cases of urinary tract infections attributed to *Escherichia coli*. The rise of extended-spectrum β -lactamase (ESBL)-producing and aminoglycoside-resistant strains complicates treatment. This research focused on identifying the occurrence of both phenotypically confirmed ESBL and AME genes in *E. coli* isolated from patients with UTIs in Sana'a, Yemen. This cross-sectional study encompassed a sample of 378 patients at Al-Kuwait University Hospital, Sana'a. Midstream urine samples were cultured and *E. coli* isolates identified via standard methods. Susceptibility to antimicrobial agents was determined through the Kirby-Bauer method, following the guidelines issued by CLSI in 2019. ESBL production was phenotypically detected and AME genes (*aac(6')*-Ib, *aac(3')*-Ila, *aph(3')*-Ia, and *ant(2')*-Ia) were detected via multiplex PCR. Among 378 samples, 167 *E. coli* isolates were identified (44.18%), of which 76 (45.5%) were ESBL-producers. AME genes were detected in 52.6% of ESBL isolates, with *aac(6')*-Ib being most frequent (39.47%), followed by *ant(2')*-Ia (31.58%) and *aph(3')*-Ia (11.84%). Co-occurrence of ≥ 2 AME genes was seen in 36.4% of isolates. Risk factors for resistance included catheterization, hospitalization, and older age. The study identified a high rate of dual antimicrobial resistance among *E. coli* isolates in Yemen underscores the need for enhanced molecular surveillance and antimicrobial stewardship programs. Empiric therapies should prioritize amikacin and carbapenems in high-risk cases.

Keywords: *Escherichia coli*, ESBL, Aminoglycoside-Modifying Enzymes, Antimicrobial Resistance, Urinary Tract Infection, Yemen

*Correspondence: siham.al91@yahoo.com

Citation: Al-Arosi SA, Bahaj SS, Al-Jaufi AY. Identification of ESBL-producing *Escherichia coli* Carrying Genes Coding Aminoglycosides Modifying Enzymes Isolated from Urinary Tract Infection Patients in Sana'a City, Yemen. *J Pure Appl Microbiol.* Published online 06 February 2026. doi: 10.22207/JPAM.20.1.17

© The Author(s) 2026. **Open Access.** This article is distributed under the terms of the [Creative Commons Attribution 4.0 International License](https://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, sharing, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

INTRODUCTION

The increasing prevalence of antibiotic-resistant pathogens, particularly multidrug-resistant *E. coli*, significantly complicates the treatment of everyday infections like UTIs, both outside and within healthcare facilities.¹ UTIs, predominantly caused by Enterobacteriaceae such as *E. coli*, account for 40% of hospital-acquired infections and are increasingly complicated by resistance to first-line therapies.^{2,3} Expansion of *E. coli* strains harboring extended-spectrum β -lactamase (ESBL) determinant, which hydrolyze cephalosporins and monobactams, has exacerbated this crisis, with resistance rates exceeding 40% in regions like the Middle East.^{4,5} Risk factors such as prolonged hospitalization, invasive procedures, and antibiotic overuse further drive resistance, limiting therapeutic options.^{6,7}

ESBLs, encoded by mobile genetic elements such as plasmids, confer resistance to β -lactams through enzymatic inactivation.⁸ ESBL-producing *E. coli* often display combined resistance to other drug classes, including aminoglycosides and fluoroquinolones, due to the clustering of resistance genes on shared plasmids.^{9,10} Carbapenems remain the last-resort treatment, but rising resistance underscores the urgency for alternative strategies.¹¹⁻¹³

Aminoglycosides, such as gentamicin and amikacin, are potent bactericidal agents used against Gram-negative infections, particularly in critically ill patients.^{14,15} However, their nephrotoxicity and ototoxicity limit prolonged use, while resistance mediated by aminoglycoside-modifying enzymes (AMEs) has surged globally.¹⁶⁻¹⁹ AMEs, including acetyltransferases (AACs) and phosphotransferases (APHs), inactivate aminoglycosides by structural modification, with genes like *aac(6')*-Ib and *ant(2')*-Ia frequently linked to ESBL plasmids.¹⁹⁻²¹ This co-resistance complicates treatment regimens and highlights the need for molecular surveillance.²²

Antimicrobial resistance, ranked fifth among global health threats by WHO in 2019, drives cross-resistance and complicates treatment in vulnerable populations.²³ The genetic co-localization of ESBL and AME genes on plasmids facilitates the spread of multidrug resistance, creating a significant public health burden.^{24,25}

Studies report high rates of co-resistance in regions with unregulated antibiotic use, such as Iran (41%) and Saudi Arabia (44.8%), driven by horizontal gene transfer.^{26,27} Risk factors like hospitalization, catheterization, and comorbidities (e.g., diabetes) further amplify resistance.^{28,29} Despite global data, gaps persist in low-resource settings like Yemen, where surveillance and stewardship programs are limited.³⁰

This study addresses the paucity of data on ESBL and aminoglycoside co-resistance in Yemen, focusing on *E. coli* isolates from UTIs in Sana'a. It aims to (1) assess the frequency of ESBL-producing *Escherichia coli* isolates, (2) identify predominant AME genes mentioned in Table 1, and (3) evaluate risk factors for co-resistance (e.g., prior hospitalization, antibiotic exposure). By characterizing resistance patterns and genetic mechanisms, this work seeks to inform local treatment guidelines and stewardship efforts, challenging the hypothesis that no association exists between AME genes and ESBL production in Yemeni UTI patients.

Although reports from various regions highlight the frequent co-detection of AME and ESBL genes, there is a notable lack of such data from Yemen. The present study is the first conducted in Sana'a to assess the co-occurrence of these resistance genes in *E. coli* isolates from individuals diagnosed with urinary tract infections.

MATERIALS AND METHODS

The design of the research

The study adopted a cross-sectional design and included patients attending either the outpatient clinic or inpatient wards of Al-Kuwait University Hospital in Sana'a, Yemen. The study was approved by the Ethics Committee, Faculty of Medicine and Health Sciences, Sana'a University, Republic of Yemen, and informed consent was obtained from the participants before enrolling in the study. A total of 378 urine specimens were collected from participants of both sexes and varying ages presenting with symptoms consistent with urinary tract infection (UTI). Individuals who had used antibiotics in the preceding two days or had contaminated samples were not included in the analysis.

Table 1. Primer sequences used for detection of Aminoglycoside-Modifying Enzyme (AME) genes

| Target gene | Primer Sequence (5'-3') | Size of amplified product (bp) |
|-------------|-------------------------------|--------------------------------|
| aac(3')-Ila | F 5'-ATGCATACGCCGAAGGC-3' | 822 bp |
| | R 5'-TGCTGGCACGATCGGAG-3' | |
| aac(6')-Ib | F 5'-TATGAGTGGCTAAATCGAT-3' | 395 bp |
| | R 5'-CCCGCTTCTCGTAGCA-3' | |
| ant(2")-Ia | F 5'-ATCTGCCCTCTGGAT-3' | 404 bp |
| | R 5'-CGAGCCTGTAGGACT-3' | |
| aph(3')-Ia | F 5'-CGAGCATCAAATGAAACTGC-3' | 623 bp |
| | R 5'-GCGTTGCCAATGATGTTACAG-3' | |

Sample collection and culture

Sterile, wide-mouthed containers were used to collect clean-catch midstream urine samples under aseptic conditions. All samples were processed within two hours of collection. Each specimen was inoculated onto Blood Agar and MacConkey Agar using a calibrated loop equivalent to 0.001 mL. Incubation was performed at 37 °C for 24 hours. A bacterial load of $\geq 10^5$ CFU/mL was considered diagnostic of infection, and only one isolate per individual was included in the analysis.

Identification of isolates

Bacterial isolates were preliminarily detected by Gram staining and colony morphology, followed by biochemical identification using standard tests including indole, citrate utilization, urease production, triple sugar iron agar, and oxidase. Confirmatory identification was done by using the Microscan WalkAway Plus 96 automated system.

Antimicrobial susceptibility testing

Antibiotic susceptibility testing was carried out using the modified Kirby-Bauer disk diffusion technique, following the guidelines provided by the Clinical and Laboratory Standards Institute (CLSI, 2019). The tested antimicrobial agents included aminoglycosides such as gentamicin, amikacin, and tobramycin, as well as β -lactam antibiotics including ceftazidime, cefotaxime, and cefepime. Interpretation of inhibition zones was based on CLSI-established breakpoints.

Phenotypic detection of ESBL

ESBL activity was assessed using the double-disk synergy test using ceftazidime and cefotaxime disks, both alone and in combination with clavulanic acid. An increase of ≥ 5 mm in the zone of inhibition with clavulanate compared to ceftazidime or cefotaxime alone indicated ESBL production. Additionally, automated confirmation was obtained using the Microscan system.

DNA extraction and PCR for AME genes detection

Genomic DNA was purified from bacterial colonies using AccuPrep Genomic DNA Extraction, Bioneer, Korea, following the instructions provided by the manufacturer. Multiplex PCR assays were performed using gene-specific primers synthesized by Microsynth AG - Balgach, Switzerland, and the Primer nucleotide sequences and expected sizes of amplicons for the targeted genes are presented in Table 1. Each Primer diluted according to volume indicated in the technical datasheet from Microsynth AG company. PCR products were separated by electrophoresis on 2% agarose gels stained with ethidium bromide and visualized under UV transillumination.

DNA Sequencing

Purified PCR products were initially submitted to Genome Medical Company (Amman, Jordan) for sequencing services. The samples were then forwarded to Macrogen Europe (Milan, Italy) for Sanger sequencing. Sequencing was performed using the BigDye® Terminator v3.1 Cycle Sequencing Kit on an ABI 3730xl DNA Analyzer (Applied Biosystems). Both forward

Table 2. Association of risk factors among ESBL and Non-ESBL *E. coli*

| Risk factors | Non-ESBL <i>E. coli</i> | | ESBL <i>E. coli</i> | | OR | CI | χ^2 | P-value |
|------------------------|----------------------------|----|------------------------|----|------|------|------------|---------------|
| | No. | % | No. | % | | | | |
| Older age | Yes | 28 | 30.7 | 48 | 63.1 | 3.86 | 2.02-7.35 | 17.51 <0.001 |
| | No | 63 | 69.3 | 28 | 36.9 | | | |
| Recent Catheterization | Yes | 14 | 15.3 | 29 | 38.1 | 3.39 | 1.63-7.05 | 11.24 0.0008 |
| | No | 77 | 84.7 | 47 | 61.9 | | | |
| Diabetic | Yes | 11 | 12 | 27 | 35.5 | 4.01 | 1.83-8.81 | 12.94 0.0003 |
| | No | 80 | 88 | 49 | 64.5 | | | |
| Kidney Disorder | Yes | 5 | 5.4 | 18 | 23.6 | 5.34 | 1.88-15.18 | 11.55 0.0007 |
| | No | 86 | 94.6 | 58 | 76.4 | | | |
| Calculi | Yes | 6 | 6.5 | 14 | 18.4 | 3.20 | 1.17-8.78 | 5.49 0.019 |
| | No | 85 | 93.5 | 62 | 81.6 | | | |
| Hospitalization/ICU | Yes | 3 | 3.3 | 17 | 22.3 | 8.45 | 2.37-30.12 | 14.28 0.00016 |
| | No | 88 | 96.7 | 59 | 77.7 | | | |
| Total | | 91 | 100% | 76 | 100% | | | |

and reverse sequencing reactions were carried out using the respective primers to ensure high accuracy and full coverage of the target genes.

Analysis and Deposition of DNA Sequences in GenBank

The nucleotide sequences were deposited in the GenBank/EMBL/DDBJ database. Each sequence was analyzed using the BLASTn algorithm against the NCBI database to determine percentage similarity with existing sequences. Accession numbers for the sequences generated in this study were retrieved from GenBank.

RESULTS

Culture and identification of isolates

Of the 378 urine samples analyzed, 274 (72.5%) exhibited significant bacterial growth, with *Escherichia coli* being the most frequently isolated pathogen (167 isolates, 44.18%). Other organisms included *Klebsiella* spp. (17.46%), *Pseudomonas* spp. (6.61%), and *Staphylococcus saprophyticus* (1.1%). Elderly patients (≥ 60 years) represented 27.8% of culture-positive cases, with burning urination (79.2%), fever (52.5%), and dysuria (51.5%) as predominant symptoms.

Demographic and clinical characteristics

The prevalence of culture-positive UTIs was higher among elderly patients (≥ 60 years) representing 27.8% of positive cases. The most commonly reported symptom was burning urination (79.2%), followed by fever (52.5%), dysuria (51.5%), and flank pain (48.9%).

Prevalence and risk factors for ESBL-producing *E. coli*

Among the 167 *E. coli* isolates, 76 (45.5%) were confirmed as ESBL producers. Statistical analysis identified hospitalization/ICU admission (OR = 8.45, 95% CI: 2.37-30.12, $p < 0.001$), kidney disorders (OR = 5.34, 95% CI: 1.88-15.18, $p = 0.0007$), and diabetes (OR = 4.01, 95% CI: 1.83-8.81, $p = 0.0003$) as significant risk factors (Table 2).

Antimicrobial resistance profile

ESBL-producing isolates exhibited near-universal resistance to β -lactams, including ampicillin (100%), cefotaxime (100%), and cefepime (100%). In contrast, carbapenems such as meropenem (81.6% susceptibility) and aminoglycosides like amikacin (85.5% susceptibility) demonstrated retained efficacy (Table 3).

Table 3. Distribution of ame genes among ESBL-producing *E. coli* isolates in Sana'a, Yemen

| Family | Antibiotics | ESBL Uropathogenic <i>E. coli</i> | | | | | |
|---|-----------------------------|-----------------------------------|---------|----|---------|----|---------|
| | | S | percent | M | percent | R | percent |
| Penicillin | Ampicillin | 1 | 1.3 | 0 | 0 | 75 | 98.7 |
| | Piperacillin | 5 | 6.6 | 3 | 3.95 | 68 | 89.47 |
| Antibiotic with β -lactamase inhibitors | Ampicillin-sulbactam | 17 | 22.4 | 12 | 15.8 | 47 | 61.8 |
| | Piperacillin-tazobactam | 33 | 43.4 | 11 | 14.47 | 32 | 42.11 |
| | Amoxicillin-clavulanic acid | 34 | 44.7 | 3 | 3.9 | 39 | 51.3 |
| Monobactam | Aztreonam | 3 | 3.9 | 1 | 1.3 | 72 | 94.7 |
| Cephalosporins-2 nd Generation | Cefoxitin | 28 | 36.8 | 8 | 10.5 | 40 | 52.6 |
| | Cefuroxime | 2 | 2.6 | 0 | 0 | 74 | 97.4 |
| Cephalosporins-3 rd Generation | Cefotaxime | 1 | 1.3 | 0 | 0 | 75 | 98.7 |
| | Ceftazidime | 2 | 2.6 | 1 | 1.3 | 73 | 96.1 |
| Cephalosporins-4 th Generation | Cefepime (Cefepime) | 2 | 2.6 | 1 | 1.3 | 73 | 96.1 |
| Tetracyclines | Tetracycline | 30 | 39.5 | 2 | 2.63 | 44 | 57.89 |
| | Tigecycline | 51 | 67.1 | 2 | 2.63 | 23 | 30.2 |
| Carbapenems | Etrapeptidem (Ertapeptidem) | 54 | 71.1 | 8 | 10.5 | 14 | 18.4 |
| | Imipenem | 57 | 75 | 6 | 7.89 | 13 | 17.11 |
| | Meropenem | 62 | 81.6 | 1 | 1.32 | 13 | 17.11 |
| Fluoroquinolones | Ciprofloxacin | 27 | 35.5 | 5 | 6.6 | 44 | 57.9 |
| Amino-glycosides | Amikacin | 65 | 85.5 | 3 | 3.9 | 8 | 10.5 |
| | Gentamicin | 50 | 65.8 | 6 | 7.89 | 20 | 26.32 |
| | Tobramycin | 45 | 59.2 | 5 | 6.58 | 26 | 34.21 |

Risk factors for AME gene carriage

Genetically confirmed aminoglycoside resistance was significantly associated recent catheterization ($p < 0.001$) as illustrated in Table 4.

Genotype-Phenotype Correlations for Aminoglycoside Resistance in ESBL-Producing *E. coli*

Of the AMG-modifying genes detected in ESBL-producing *E. coli* isolates, the presence of *aac(6')-Ib* was strongly associated with a resistant phenotype to gentamicin (70%) and tobramycin (66.7%), but not to amikacin. Similarly, *ant(2')-Ia* correlated with resistance to tobramycin (66.7%) and, to a lesser extent, gentamicin (54.2%). The less frequent genes *aph(3')-Ia* and *aac(3')-Ila* showed distinct profiles, with *aph(3')-Ia* conferring high-level gentamicin resistance (77.8%) and *aac(3')-Ila* being linked to universal gentamicin resistance (100%) as shown in Table 5.

Similarity of DNA sequences of AME-genes produced by ESBL *E. coli*

Sequences of each resistance gene of the clinical pathogenic isolates have been deposited in GenBank to determine the similarity between the sequences of the present study and that previously deposited in GenBank by other investigators for the same genes.

Regarding the nucleotide sequence of the amplified *acc(6')-Ib* gene, it was found that 45 bacterial sequences of aminoglycoside (6) N-acetyltransferase of different bacterial species were similar by 100% with *acc(6')-Ib* gene of *E. coli*. Among these genes, aminoglycoside (6) N-acetyltransferase of *Shigella sonnei* with accession no. LC310955.1. and of *E. coli* with accession no. MF495900.

The nucleotide sequence of the *ant(2')-Ia* gene from *Escherichia coli* exhibited 99%-100% identity to a similar gene from 39 various bacterial strains producing the same gene, among these

genes, aminoglycoside nucleotidyltransferase ant (2")-la of *Pseudomonas aeruginosa* and *E. coli* isolate (accession no. NG_052369.1 and MF495900, respectively).

The sequence of *aph(3')-la* gene of *E. coli* of the present study revealed that this gene was similar by 99% with 10 different bacterial strains having *aph(3')-la* genes. Among these genes, aminoglycoside (3')phosphotransferase of *Klebsiella pneumonia* with accession no. MF495903 and *E. coli* strain P225M with accession number CP044348.1.

The sequence of *acc (3')-Ila* gene of *E. coli* was similar by 99% to aminoglycoside (3) N-acetyl transferase of *Klebsiella pneumonia* with accession no. PV023000.1 and *E. coli* strain AVS0970 with accession no. CP124503.1.

Determination of AME Gene Accession Numbers

The nucleotide sequences of the four AME genes identified in this study were deposited in GenBank. Sequence similarity was confirmed via BLASTn analysis against the NCBI database, revealing 99%-100% identity with previously

Table 4. Correlation between risk factors and AME gene-mediated resistance in ESBL-producing *E. coli*

| Risk factors | ESBL-producing <i>E. coli</i> with AMG resistance | | | | ESBL-producing <i>E. coli</i> without AMG resistance | | | | OR | Lower | Upper | χ^2 | P-value | | | | | |
|------------------------|---|----|---------------------------|----|--|-------|------|-------|------|--------|-------|----------|---------|--|--|--|--|--|
| | (phenotypic or genotypic) | | (phenotypic or genotypic) | | CI | | | | | | | | | | | | | |
| | No. | % | No. | % | Lower | Upper | | | | | | | | | | | | |
| Older age | Yes | 28 | 63.6 | 20 | 62.5 | 1.1 | 0.41 | 2.7 | 0.01 | 0.919 | | | | | | | | |
| | No | 16 | 36.4 | 12 | 37.5 | | | | | | | | | | | | | |
| Recent Catheterization | Yes | 28 | 63.6 | 1 | 3.1 | 54.2 | 6.8 | 435.9 | 28.7 | <0.001 | | | | | | | | |
| | No | 16 | 36.4 | 31 | 96.9 | | | | | | | | | | | | | |
| Diabetic | Yes | 17 | 38.6 | 10 | 31.3 | 1.4 | 0.53 | 3.6 | 0.44 | 0.507 | | | | | | | | |
| | No | 27 | 61.4 | 22 | 68.8 | | | | | | | | | | | | | |
| Kidney Disorder | Yes | 9 | 20.5 | 9 | 28.1 | 0.66 | 0.23 | 1.9 | 0.6 | 0.437 | | | | | | | | |
| | No | 35 | 79.5 | 23 | 71.9 | | | | | | | | | | | | | |
| Calculi | Yes | 9 | 20.5 | 5 | 15.6 | 1.4 | 0.42 | 4.6 | 0.29 | 0.592 | | | | | | | | |
| | No | 35 | 79.5 | 27 | 84.4 | | | | | | | | | | | | | |
| Hospitalization/ICU | Yes | 8 | 18.2 | 9 | 28.1 | 0.57 | 0.19 | 1.7 | 1.1 | 0.304 | | | | | | | | |
| | No | 36 | 81.8 | 23 | 71.9 | | | | | | | | | | | | | |
| Total | | 44 | 100 | 32 | 100 | | 76 | | | | | | | | | | | |

Table 5. Genotype-Phenotype Correlations for Aminoglycoside Resistance in ESBL-Producing *E. coli*

| Phenotypically resistance/ Genetically resistance | | Phenotypically resistance | | | | | | Sensitive (%) | Resistant (%) | Sensitive (%) | Resistant (%) | Sensitive (%) | Resistant (%) | | | | | | |
|---|---|---------------------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|--|--|--|--|--|--|
| | | Amikacin | | | Gentamycin | | | | | | | | | | | | | | |
| | | Sensitive (%) | Resistant (%) | Sensitive (%) | Resistant (%) | Sensitive (%) | Resistant (%) | | | | | | | | | | | | |
| AMG encoding genes among ESBL-producing <i>E. coli</i> isolates | aac(6')-lb N = 30 ant(2")-la N = 24 aph(3')-la N = 9 aac(3')-Ila N = 3 | 22 (53.3%) | 8 (26.7%) | 9 (30%) | 21 (70%) | 10 (33.3%) | 20 (66.7%) | | | | | | | | | | | | |
| | | 16 (66.7%) | 8 (33.3%) | 11 (45.8%) | 13 (54.2%) | 8 (33.3%) | 16 (66.7%) | | | | | | | | | | | | |
| | | 7 (77.8%) | 2 (22.2%) | 2 (22.2%) | 7 (77.8%) | 5 (55.6%) | 4 (44.4%) | | | | | | | | | | | | |
| | | 1 (33.3%) | 2 (66.7%) | 0 (0%) | 3 (100%) | 1 (33.3%) | 2 (66.7%) | | | | | | | | | | | | |

Table 6. Determination of accession numbers by GenBank

| Sequence_ID | Identifier Organism GenBank accession number |
|--------------------|--|
| Seq-1: aac(6')-Ib | <i>Escherichia coli</i> PX219619 |
| Seq-2: ant(2")-Ia | <i>Escherichia coli</i> PX219620 |
| Seq-3: aph(3')-Ia | <i>Escherichia coli</i> PX219621 |
| Seq-4: aac(3')-Ila | <i>Escherichia coli</i> PX219618 |

reported homologs. Unique accession numbers were assigned to each gene, as listed in Table 6.

DISCUSSION

The findings indicate a high prevalence of multidrug-resistant (MDR) *Escherichia coli* among UTI patients in Sana'a, Yemen. Nearly half of the *E. coli* isolates were ESBL producers, and over half of these showed concurrent resistance to aminoglycosides. These findings align with regional trends, reinforcing *E. coli* as the leading uropathogen with increasing resistance rates.

The 45.5% prevalence of ESBL-producing *E. coli* observed here is comparable to reports from Egypt (44.6%), Iran (41%), and Pakistan (40%).⁴⁻⁶ However, higher rates have been reported in Jordan, Syria (50%-62%),⁷ while lower rates were seen in parts of Saudi Arabia (27.4%-33%).⁸ These differences likely reflect variability in antimicrobial stewardship, diagnostic capacity, and healthcare infrastructure.

Our results show universal resistance of ESBL-producing isolates to penicillins and third-generation cephalosporins similar to patterns observed in Egypt, Iran, and Saudi Arabia.⁹⁻¹¹ In contrast, carbapenems and amikacin remained the most effective agents, making them essential for empirical treatment in high-risk cases similar to results reported by a study conducted in Pakistan.¹²

Notably, 60.5% of ESBL-producing isolates showed phenotypic resistance to aminoglycosides. PCR analysis confirmed that 52.6% carried at least one AME gene, with aac(6')-Ib being the most prevalent. These findings are in line with studies from Sudan, Egypt, and Spain.¹³⁻¹⁵ However, some studies, such as those from Tunisia and Tehran, found aac(3')-Ila to be more common,^{16,17}

suggesting regional variability in resistance gene profiles. Another study conducted in Iran reported that the most frequent AME-related genes were ant(2")-Ia and aph(3')-Ia, followed by aac(3')-Ila.¹⁸

A strong genotype-phenotype correlation was observed, especially with aac(6')-Ib, ant(2")-Ia and aac(3')-Ila and tobramycin/gentamicin resistance. These findings corroborate global data from Switzerland and the Middle East,^{17,18} further highlighting the diagnostic value of molecular assays in resistance surveillance.

Interestingly, some isolates (7.9%) demonstrated phenotypic resistance without detectable AME genes, suggesting alternative mechanisms such as 16S rRNA methylation or efflux pumps. Further genomic studies are warranted to elucidate these mechanisms.¹⁹

Our risk factor analysis showed that only catheterization was independently associated with both ESBL and AME gene carriage. This pattern is supported by data from China, Sierra Leone, and France,²⁰⁻²³ underscoring the role of healthcare exposure in promoting resistance. Interestingly, comorbidities like diabetes and kidney disorders were not significantly associated with AME gene carriage in our cohort, unlike findings from other studies.²⁴

All sequences of the detected amplicons were aligned and showed 99%-100% identity with the reported target genes accessed from NCBI. Similar results were obtained in studies from Egypt and Spain.^{10,31} The observed sequence homology across distinct bacterial species strongly suggests the occurrence of natural horizontal gene transfer of these resistance genes.

This study has several limitations. First, the sample size, while sufficient for initial analysis, may not fully capture the diversity of resistance patterns across different populations. Second, the study focused on specific AME genes (aac(6')-Ib, aac(3')-Ila, aph(3')-Ia, ant(2")-Ia), and did not investigate other resistance mechanisms such as 16S rRNA methyltransferases or efflux pumps, which may contribute to aminoglycoside resistance. Finally, whole-genome sequencing was not performed, which limits the ability to track plasmid-mediated gene transfer or clonal spread.

To the best of our knowledge, this is the first study in Yemen to report the co-occurrence of ESBL production and AME genes particularly *aac(6')-Ib* in uropathogenic *E. coli*.

CONCLUSION

These findings highlight an emerging threat of multidrug-resistance in a resource-limited setting and underscore the urgent need for national antimicrobial resistance surveillance and stewardship programs in Yemen. Given the high rates of co-resistance to β -lactams and aminoglycosides, empirical therapy for complicated UTIs should prioritize carbapenems (e.g., meropenem) and amikacin, especially in patients with healthcare-associated risk factors such as catheterization or recent hospitalization.

ACKNOWLEDGMENTS

None.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interest.

AUTHORS' CONTRIBUTION

SAAA conceptualized the study, applied methodology, performed data collection and formal analysis. SSB performed validation. SSB and AYAJ supervised the study. AYAJ performed project administration. SAAA wrote the manuscript. SSB and AYAJ reviewed and edited the manuscript. All authors read and approved the final manuscript for publication.

FUNDING

None.

DATA AVAILABILITY

All datasets generated or analyzed during this study are included in the manuscript.

ETHICS STATEMENT

This study was approved by the Ethics Committee, Faculty of Medicine and Health Sciences, Sana'a University, Republic of Yemen.

INFORMED CONSENT

Written informed consent was obtained from the participants before enrolling in the study.

REFERENCES

1. Cerceo E, Deitelzweig SB, Sherman BM, Amin AN. Multidrug-resistant pathogens in the hospital setting: overview, implications for clinical practice, and emerging treatment options. *Microb Drug Resist.* 2016;22(5):412-431. doi: 10.1089/mdr.2015.0220
2. Pandit R, Awal B, Shrestha SS, Joshi G, Rijal BP, Parajuli NP. Extended-spectrum β -lactamase (ESBL) genotypes among multidrug-resistant uropathogenic *Escherichia coli* clinical isolates from a teaching hospital of Nepal. *Interdiscip Perspect Infect Dis.* 2020;2020:6525826. doi: 10.1155/2020/6525826
3. Karam MRA, Habibi M, Bouzari S. Urinary tract infection: pathogenicity, antibiotic resistance and development of effective vaccines against uropathogenic *Escherichia coli*. *Mol Immunol.* 2019;108:56-67. doi: 10.1016/j.molimm.2019.02.007
4. Knothe H, Shah P, Krcmery V, Antal M, Mitsuhashi S. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of *Klebsiella pneumoniae* and *Serratia marcescens*. *Infection.* 1983;11(6):315-317. doi: 10.1007/BF01641355
5. Abalkhail A, AlYami AS, Alrashedi SF, et al. The prevalence of multidrug-resistant *Escherichia coli* producing ESBL among male and female patients with urinary tract infections in Riyadh Region, Saudi Arabia. *Healthcare (Basel).* 2022;10(9):1778. doi: 10.3390/healthcare10091778
6. Ahmed MZ, Rao T, Ahmad W, et al. Drugs resistance in bacterial diseases. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. *Biochemistry of Drug Resistance*. Springer. 2021:33-56. doi: 10.1007/978-3-030-76320-6_2
7. Caneiras C, Lito L, Melo-Cristino J, Duarte A. Community- and hospital-acquired *Klebsiella pneumoniae* urinary tract infections in Portugal: virulence and antibiotic resistance. *Microorganisms.* 2019;7(5):138. doi: 10.3390/microorganisms7050138
8. Bajaj P, Singh NS, Virdi JS. *Escherichia coli* β -lactamases: what really matters. *Front Microbiol.* 2016;7:417. doi: 10.3389/fmicb.2016.00417
9. Rezai MS, Salehifar E, Rafiei A, et al. Characterization of multidrug resistant extended-spectrum beta-lactamase-producing *Escherichia coli* among uropathogens of pediatrics in North of Iran. *Biomed Res Int.* 2015;2015(1):309478. doi: 10.1155/2015/309478
10. Abo-State MA, Saleh YE, Ghareeb HM. Prevalence and sequence of aminoglycoside-modifying enzymes genes among *E. coli* and *Klebsiella* species isolated from Egyptian hospitals. *J Radiat Res Appl Sci.* 2018;11(4):408-415. doi: 10.1016/j.jrras.2018.07.004
11. Bassetti M, Peghin M, Pecori D. The management of multidrug-resistant Enterobacteriaceae. *Curr*

12. *Opin Infect Dis.* 2016;29(6):583-594. doi:10.1097/QCO.00000000000000314

13. Khan ZU, Haq TU, Ahmad J, Ullah R, Khattak AR. Prevalence of ESBL-producing and carbapenem-resistant *Escherichia coli* in urinary tract infection from a tertiary care hospital. *Indus J Biosci Res.* 2025;3(7):182-185. doi: 10.70749/ijbr.v3i7.1833

14. Guo J, Li C. Molecular epidemiology and decreased susceptibility to disinfectants in carbapenem-resistant *Acinetobacter baumannii* isolated from intensive care unit patients in central China. *J Infect Public Health.* 2019;12(6):890-896. doi: 10.1016/j.jiph.2019.05.010

15. Erbay A, Bodur H, Akyncı E, Colpan A. Evaluation of antibiotic use in intensive care units of a tertiary care hospital in Turkey. *J Hosp Infect.* 2005;59(1):53-61. doi: 10.1016/j.jhin.2004.07.026

16. Mazzariol A, Bazaj A, Cornaglia G. Multi-drug-resistant Gram-negative bacteria causing urinary tract infections: a review. *J Chemother.* 2017;29(Sup1):2-9. doi: 10.1080/1120009X.2017.1380395

17. Harbaoui S, Ferjani S, Abbassi MS, et al. Genetic background of aminoglycoside-modifying enzymes in various genetic lineages of clinical aminoglycosides-resistant *E. coli* and *K. pneumoniae* isolates in Tunisia. *J Appl Microbiol.* 2024;135(7):lxae164. doi: 10.1093/jambo/lxae164

18. Du Toit M. Therapeutic drug monitoring of gentamicin and amikacin in hospitalised patients in a private hospital, Western Cape [Doctoral dissertation]. North-West University. 2019. <https://hdl.handle.net/10394/33757>

19. Akrami S, Khoshnood S, Koupaei M, et al. Molecular evaluation of aminoglycoside resistance and biofilm formation potential in *Escherichia coli* isolates collected from hospitalized patients. *Jundishapur J Microbiol.* 2024;17(6):e144678. doi: 10.5812/jjm-148101

20. Wargo KA, Edwards JD. Aminoglycoside-induced nephrotoxicity. *J Pharm Pract.* 2014;27(6):573-577.

21. Ramirez MS, Tolmasky ME. Aminoglycoside modifying enzymes. *Drug Resist Updat.* 2010;13(6):151-171. doi: 10.1016/j.drup.2010.08.003

22. Fernandez-Martinez M, Miro E, Ortega A, et al. Molecular identification of aminoglycoside-modifying enzymes in clinical isolates of *Escherichia coli* resistant to amoxicillin/clavulanic acid isolated in Spain. *Int J Antimicrob Agents.* 2015;46(2):157-163. doi: 10.1016/j.ijantimicag.2015.03.008

23. *pneumoniae, Escherichia coli, and Proteus mirabilis* in Poland. *Int J Antibiolut.* 2014;2014(1):935842. doi: 10.1155/2014/935842

24. Bitew G, Dagnew M, Dereje M, et al. Burden of multi-drug resistant bacterial isolates and its associated risk factors among UTI-confirmed geriatrics in Gondar town. *Sci Rep.* 2025;15(1):14270. doi: 10.1038/s41598-025-89123-9

25. Iredell J, Brown J, Tagg K. Antibiotic resistance in Enterobacteriaceae: mechanisms and clinical implications. *BMJ.* 2016;352:h6420. doi: 10.1136/bmj.h6420

26. Doi Y, Wachino JI, Arakawa Y. Aminoglycoside resistance: the emergence of acquired 16S ribosomal RNA methyltransferases. *Infect Dis Clin North Am.* 2016;30(2):523-537. doi: 10.1016/j.idc.2016.02.011

27. Hashemizadeh Z, Kalantar-Neyestanaki D, Mansouri S. Clonal relationships, antimicrobial susceptibilities, and molecular characterization of extended-spectrum beta-lactamase-producing *Escherichia coli* isolates from urinary tract infections and fecal samples in Southeast Iran. *Rev Soc Bras Med Trop.* 2018;51(1):44-51. doi: 10.1590/0037-8682-0080-2017

28. Alyamani EJ, Khiyami AM, Booq RY, Majrashi MA, Bahwerth FS, Rechkina E. The occurrence of ESBL-producing *Escherichia coli* carrying aminoglycoside resistance genes in urinary tract infections in Saudi Arabia. *Ann Clin Microbiol Antimicrob.* 2017;16(1):1-13. doi: 10.1186/s12941-016-0177-6

29. Anesi JA, Lautenbach E, Tamma PD, et al. Risk factors for extended-spectrum β -lactamase-producing enterobacteriales bloodstream infection among solid-organ transplant recipients. *Clin Infect Dis.* 2021;72(6):953-960. doi: 10.1093/cid/ciaa190

30. Carrillo-Larco RM, Anza-Ramirez C, Saal-Zapata G, et al. Type 2 diabetes mellitus and antibiotic-resistant infections: a systematic review and meta-analysis. *J Epidemiol Community Health.* 2022;76(1):75-84. doi: 10.1136/jech-2020-216029

31. Mohapatra S, Panigrahy R, Tak V, et al. Prevalence and resistance pattern of uropathogens from community settings of different regions: an experience from India. *Access Microbiol.* 2022;4(2):000321. doi: 10.1099/acmi.0.000321

32. Bodendoerfer E, Marchesi M, Imkamp F, Courvalin P, Böttger EC, Mancini S. Co-occurrence of aminoglycoside and β -lactam resistance mechanisms in aminoglycoside-non-susceptible *Escherichia coli* isolated in the Zurich area, Switzerland. *Int J Antimicrob Agents.* 2020;56(1):106019. doi: 10.1016/j.ijantimicag.2020.106019